Q2 2025 Biogaia AB Earnings Call Transcript

Jul 18, 2025 / 07:30 AM GMT

Release Date Price: $9.58

Transcript

Key Points

Positve

BioGaia AB (BIOGY) reported a 5% increase in sales for Q2 2025, with a significant 13.2% growth when excluding currency effects.
Sales in the Asia Pacific region increased by 15%, driven by strong performance in Indonesia, Australia, and South Korea.
The adult health segment saw a robust growth of 15%, with a 23% increase when excluding currency effects, particularly in the US and Indonesia.
BioGaia AB (BIOGY) successfully launched direct sales in the Netherlands through Amazon and Bol, surpassing expectations.
The company announced the formation of a new subsidiary, BioGaia New Sciences, focusing on expanding into new areas such as skin health.

Negative

Sales in Europe, Middle East, and Africa decreased by 1%, with notable declines in Turkey, France, and Germany.
EBIT decreased by 20% to 108 million SEK, with an EBIT margin of 27%, down from 35% in the previous year.
Operating expenses increased by 25%, primarily due to higher sales and marketing costs in the US and Canada.
Cash flow from operating activities decreased by 35% compared to the previous year, impacted by lower operating profit.
The gross margin slightly declined to 73% from 74% in the previous year, affected by geographic and seasonal variations.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BIOGb.ST - Biogaia AB
Q2 2025 Biogaia AB Earnings Call
Jul 18, 2025 / 07:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
This is Teresa Agnew, CEO of BioGaya, and we are here to report on our Q2 2025 results.

For Q2, our sales were 405 million sec, which represents growth of 5%. That was mainly due to higher sales in America, specifically North America and Asia Pacific. We did have growth of 13.2% when you exclude currency effects for the quarter.

Sales in Europe, Middle East, Africa decreased by 1%. In Asia Pacific, sales increased by 15%, and in the Americas, sales increased by 5%. Our EBIT was 108 million sac, which was a decrease of 20%, and our e-bit margin for the quarter was 27%.

We also, over the period of Q2, announced that we are establishing direct sales in the Netherlands for the first time. This is a market in Europe where we

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.